Compare Ginkgo Bioworks Holdings Inc (DNA) vs Levi Strauss & Co. (LEVI) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

Levi Strauss (LEVI) trades at $19.51, down 4.97% on the day, with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 62.81% gross margins and 8.83% net income margin, supported by four consecutive quarterly earnings beats. Analyst consensus remains strongly bullish with a $29 price target representing 49% upside potential. Recent developments include the appointment of a new CFO and continued momentum in denim demand driving revenue growth.

The stock presents a compelling value opportunity with attractive valuation multiples (P/E 12.53, P/S 1.12) and strong cash flow generation. However, near-term technical weakness and recent cybersecurity concerns require monitoring. The company's direct-to-consumer strategy and international expansion provide growth catalysts, though execution risks and market volatility remain considerations for investors.